Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could Help [Seeking Alpha]
Geron Corporation (GERN)
Last geron corporation earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
geron.com/investors
Company Research
Source: Seeking Alpha
Despite efforts to boost Rytelo's use in first and second-line therapy (now 36%, up from 30%), revenue growth remains elusive for GERN. Recent leadership changes include the departure of COO Andrew Grethlein and CCO Jim Ziegler, with Ahmed ElNawawi stepping in as CCO. GERN could announce an EU partner for Rytelo near-term, with Rytelo already approved in the EU, and results from a phase 3 myelofibrosis trial in 2026 are possible too. Klaus Vedfelt/DigitalVision via Getty Images Geron Corporation ( GERN ) now has five full quarters of the Rytelo (imetelstat) launch behind it, but the launch isn't going from strength to strength. In August, I rated GERN a buy, noting a This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation fo
Show less
Read more
Impact Snapshot
Event Time:
GERN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GERN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GERN alerts
High impacting Geron Corporation news events
Weekly update
A roundup of the hottest topics
GERN
News
- Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection PointsPR Newswire
- Geron Corporation (NASDAQ:GERN) is favoured by institutional owners who hold 64% of the company [Yahoo! Finance]Yahoo! Finance
- Geron (NASDAQ:GERN) had its price target lowered by analysts at Needham & Company LLC from $5.00 to $4.00. They now have a "buy" rating on the stock.MarketBeat
- Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business HighlightsBusiness Wire
- Geron Corporation to Present at Upcoming Investor ConferencesBusiness Wire
GERN
Earnings
- 11/5/25 - In-Line
GERN
Sec Filings
- 11/7/25 - Form 10-Q
- 11/5/25 - Form 8-K
- 10/20/25 - Form 3
- GERN's page on the SEC website